Abstract: Methods for forming a metal silicide are disclosed. An exemplary method includes providing a substrate in a reaction chamber, performing a thermal deposition process to form a metal silicide film, and optionally forming a cap layer (e.g., directly) on the metal silicide. Exemplary method can further include performing a soak process. Methods described herein may be performed without generating a plasma.

Abstract: Methods of forming a transition metal silicide are disclosed. Exemplary methods include selectively forming a transition metal silicide on a first surface relative to a second surface. The step of forming the transition metal silicide can include providing a catalyst. Additionally or alternatively, exemplary methods can include a cleaning and/or surface treatment step prior to forming the transition metal silicide. Methods described herein may be particularly useful in forming structures suitable for NMOS devices.

Abstract: A VEGF-targeting VHH, a bispecific antibody targeting PD-1 and VEGF developed on the basis of the VHH, and an application thereof. The VHH has high stability, and has multiple excellent effects, such as ease of expression and purification. The constructed bispecific antibody targeting PD-1 and VEGF has high stability, can target enrichment in a high-expression VEGF tumor region, has good medicinal efficacy and safety, and has excellent treatment potential.

Abstract: Disclosed is a method, system and apparatus for depositing a composite film, comprising providing a substrate in a reaction chamber, depositing a first material layer comprising a first metal nitride according to a first cyclic deposition process, depositing a second material layer comprising aluminum carbide according to a second cyclic deposition process and depositing a third material layer comprising a second metal nitride according to a third cyclic deposition process.

Abstract: A VEGF-targeting VHH, a bispecific antibody targeting PD-1 and VEGF developed on the basis of the VHH, and an application thereof. The VHH has high stability, and has a plurality of excellent effects, such as ease of expression and purification. The constructed bispecific antibody targeting PD-1 and VEGF has high stability, can target enrichment in a high-expression VEGF tumor region, has good medicinal efficacy and safety, and has excellent treatment potential.

Abstract: The present invention relates to a bispecific antibody that binds to human CD19 and CD3, wherein the bispecific antibody is composed of a Fab fragment which specifically recognizes a cell membrane antigen and a single-chain antibody which recognizes a CD3 molecule, where the single-chain antibody which recognizes the CD3 molecule is linked to the C-terminus of the CH1-region peptide fragment of the Fab fragment through a hydrophilic linker peptide-linker; and where the Fab fragment which specifically recognizes a cell membrane antigen contains a Fab structure which specifically recognizes a human CD19 antigen, and the bispecific antibody has the following structure: where the linker peptide-linker is composed of 8-20 hydrophilic amino acids.